Nystagmus Assessment for Patients Consulting in the Emergency Department for Acute Vertigo

Sponsor
CHU de Quebec-Universite Laval (Other)
Overall Status
Recruiting
CT.gov ID
NCT05176015
Collaborator
(none)
120
1
4
22.5
5.3

Study Details

Study Description

Brief Summary

This pilot study is perfomed to validate and document faisability of the use of Frenzel lens and the use of a diagnostic algorithm for the assessment of a special sign (nystagmus) observe in the eyes of patients consulting in the emergency department for an acute episode of vertigo/dizziness/imbalance.

Condition or Disease Intervention/Treatment Phase
  • Device: Frenzel Lens
  • Diagnostic Test: Diagnostic Algorithm
N/A

Detailed Description

This pilot study is a randomized controlled trial 2 by 2 design to allocated randomly the Frenzel lens and the diagnostic algorithm. There is no use of sham lens. The usual care opposed to the diagnostic algorithm will be questionned only on the perception of nystagmus by the clinician and the use of repositionning particules technique. The only blindings will be the patients about the use of the algorithm and the outcomes assessor about the use or not of Frenzel lens and the use or not of the diagnostic algorithm.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Randomized Controlled Trial on Nystagmus Assessment for Patients Consulting for Acute Vertigo in the Emergency Department With/Without Frenzel Lens With/Without Form: A Pilot Study
Actual Study Start Date :
Jan 15, 2022
Anticipated Primary Completion Date :
Sep 30, 2023
Anticipated Study Completion Date :
Nov 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Frenzel Lens with Diagnostic Algorithm

Frenzel lens will be applied on patients' eyes during different diagnostic manoeuvre to assess if a nystagmus is present and if present describe its main characteristic. Without mentionning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging

Device: Frenzel Lens
pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.

Diagnostic Test: Diagnostic Algorithm
A diagnostic algorithm using the Tittrate approach: continuous, Intermittant, trigger or spontaneous. The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different manoeuvres: HINTS+ battery, Dix-Hallpike test, Supine Head Roll test. Different Particule Repositionning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvres. Risk Scrore is used to assess stroke risk for transient ischemic attack: ABCD2 and the Canandian TIA Risk Score

Experimental: Frenzel Lens without Diagnostic Algorithm

Frenzel lens will be applied on patients' eyes during different diagnostic manoeuvres to assess if a nystagmus is present and describe its main characteristics. No diagnostic algorithm will be used to interpret nystagmus.

Device: Frenzel Lens
pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.

Experimental: No Frenzel Lens with Diagnostic Algorithm

Nystagmus assessment in different manoeuvres is performed without the use of Frenzel lens. Without mentionning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging

Diagnostic Test: Diagnostic Algorithm
A diagnostic algorithm using the Tittrate approach: continuous, Intermittant, trigger or spontaneous. The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different manoeuvres: HINTS+ battery, Dix-Hallpike test, Supine Head Roll test. Different Particule Repositionning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvres. Risk Scrore is used to assess stroke risk for transient ischemic attack: ABCD2 and the Canandian TIA Risk Score

No Intervention: No Frenzel Lens and No Diagnostic Algorithm

The emergency physician is performing the assessment of nystagmus and its interpretation as usual. The Frenzel lens and the diagnostic algorithm are not used.

Outcome Measures

Primary Outcome Measures

  1. Rate of Nystagmus detection per participant [Day 0]

    During eye examination, nystagmus will be characterized according to prominent direction of the fast phase (patients' left, patients' right, up, down, rotational),with their clinical setting or trigger. Overall rate of nystagmus detection by participant. (Rate of typical nystagmus for bening paroxismal peripheral vertigo in the Dix-Hallpike maneuvre or Supine Head Roll Test. Rate of nystagmus detection in the initial physical exam)

Secondary Outcome Measures

  1. Emergency Department Lenght of stay [Day 0, from triage time to Emergency Department departure (admission or home discharge)]

    Time spent at the emergency department from triage to time of departure for hospital admission or for home discharge assessed up to 48 hours

  2. Rate of neuro-imaging per participant [From day 0 to 12 weeks]

    Any imaging to investigate acute intra-cerebral lesion and/or the neck/brain vascular. anomaly : computed tomography imaging; computed tomography angiogram; magnetic resonance angiography; magnetic resonance imaging, vascular neck ultrasound imaging.

  3. Rate of acute stroke per participant [From day 0 to 12 weeks]

    Any acute stroke, hemorrhagic or ischemic, diagnosed by neuro-imaging: computed tomography or magnetic resonnance imaging

  4. Rate of symptomatic central lesion per participant [From day 0 to 12 weeks]

    Any central lesion diagnosed by computed tomography or magnetic resonnance imaging that may be related to the initial presentation of vertigo/dizziness/imbalance

  5. Rate of specialised consultations for vertigo/dizziness/imbalance per participant [From day 0 to 12 weeks]

    Any specialised consultations (neurology, ENT, cardiology or similar) to investigate the acute vertigo/dizziness/imbalance with the final diagnosis. Summarisation of final diagnosis.

  6. Rate of acute vertigo/dizziness/imbalance related hospitalisation per participant [From day 0 to 12 weeks]

    Admission to hospital directly related to vertigo/dizziness/imbalance may be immediate to initial visit or delayed.

  7. Rate of subsequent Emergency Department Visit for Vertigo/dizziness/imbalance per participant [From day 0 t0 12 weeks]

    Return visit to the emergency department for vertigo/dizzness/imbalance as chief complaint.

  8. Rate of New Atrial Fibrillation [From day 0 to 12 weeks]

    Atrial fibrillation detected by the initial visit electrocadiogram or by long-term cardiac rhythm monitoring (Holter or loop recorder).

  9. Rate of New Stroke at 12 weeks [At 12 weeks]

    A stroke free status will be assessed by a validated questionnaire by telephone at tree months and all specialised consultations and neuroimaging will be reviewed for acute stroke diagnosis,

  10. Rate of the use of Particules Repositionning Technique [Day 0]

    Once Peripheral Paroxystic Vertigo diagnosis is being diagnosed with the Dix-Hallpike test or with the Supine Head Roll test, the use of particules repositionning technique, Epley or Gufoni maneuvres, will be noted with their immediate impact on acute vertigo.

  11. Rate of Emergency Department Visit Return for Benign Peripheral Paroxystic Vertigo according to Typical Nystagmus [From day 0 to 12 weeks]

    Rate of Emergency Department Visit Return for Benign Peripheral Paroxystic Vertigo according to Typical Nystagmus: direction, duration

  12. Initial managment self appreciation of patient presenting in the ED for an acute episode of vertigo/dizziness/imbalance [Day 0]

    Simple question answered on a likert scale at the end of the ED encounter. 0% worst, 100% best appreciation.

  13. Adverse Events [From day 0 to 12 weeks]

    Combination of stroke, death, neurosurgery, intervenional neuroradiology, thrombolytic therapy

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • New episode of acute vertigo/dizziness/imbalance occuring during the 7 last days

  • Must be able to consent.

Exclusion Criteria:
  • No traumatic context before symptoms onset

  • No intoxication context

  • Glycemia ≤ 3,0 mmol/L

  • Only one participation is permitted

  • Not able to speak fluently in French or English.

  • Reachable for 3 month follow-up

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Notre-Dame-de-Fatima La Pocatiere Quebec Canada G0R 1Z0

Sponsors and Collaborators

  • CHU de Quebec-Universite Laval

Investigators

  • Principal Investigator: Pierre La Rochelle, MD, MSc, Universite Laval

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pierre La Rochelle, Chief Investigator, CHU de Quebec-Universite Laval
ClinicalTrials.gov Identifier:
NCT05176015
Other Study ID Numbers:
  • MP-CIBSSSBSL-2021-03
First Posted:
Jan 4, 2022
Last Update Posted:
Feb 16, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Pierre La Rochelle, Chief Investigator, CHU de Quebec-Universite Laval
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2022